Sartorius Recombumin

Our Recombumin® recombinant human albumin portfolio is produced in a proprietary yeast strain and is the culmination of four decades of recombinant albumin research. The Recombumin® portfolio is made up of two recombinant human albumin formulations: Recombumin® Prime and Recombumin® Elite.

Manufactured in an ICH Q7 cGMP facility, our Recombumin® portfolio offers your process batch-to-batch consistency and predictable performance. Utilized in FDA, EMEA and MHRA approved products, early and late-stage clinical biopharmaceutical candidates, and as a coating for marketed high-class medical devices, the Recombumin® portfolio has excellent market exposure. With an extensive regulatory package and drug master files registered in key markets, the Recombumin® portfolio is a solution for those developing high-quality products, that demand high quality and consistent raw materials.

We know that the formulation of your albumin really matters, as the manufacturing process and the ligands associated with albumin drive differential performance. Use the experience and know-how of our Sartorius team to help make your project a success!

Recombumin® Elite | Key Facts
Salt-based recombinant human albumin formulation
Recombumin® Elite is used both up and downstream in several advanced therapies currently in development.
Recombumin® Elite has an extensive DMF registered in key markets.

Recombumin® Prime | Key Facts
Octanoate and polysorbate-80 based recombinant human albumin formulation.
Recombumin® Prime has supported the manufacture of over 210 million doses of paediatric vaccine.
Recombumin® Prime is utilized in the manufacture of medical devices, forming an anti-adsorptive biological interface.
Recombumin® Prime (50 mL) is USP-NF compliant.